CLX

Business Profile & Competitive Position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. Its fiscal 2026 net sales were $6.7 billion, generated by roughly 9,200 employees across about 25 countries and sold into approximately 95 markets. The consumer side is anchored by brands such as Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while the professional division markets Purell, CloroxPro, and Clorox Healthcare. The April 2026 completion of the GOJO Industries acquisition added hand-hygiene capabilities and expanded the business-to-business footprint.

The company’s reported net margin of 8.7% is positive, which means core operations are profitable. By contrast, the ROE of -1,893.5% is not an operating-loss signal; mathematically, a positive net margin and a deeply negative ROE imply a negative book-equity base, usually the result of accumulated capital returns, share buybacks, and accounting adjustments rather than current cash burn. That distinction matters when assessing competitive position: the margin supports the idea that the brand portfolio can still price products above input costs, while the ROE number simply tells you the balance sheet is highly leveraged on an accounting basis. One structural vulnerability that is straightforward from the data is customer concentration. Walmart accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half of net sales. That concentration is common in household products, but it gives large retailers meaningful bargaining leverage and raises the stakes for any supply, pricing, or shelf-space disruption.

Financial Posture

Clorox currently carries a market capitalization of $12.7 billion and trades at a P/E of 21.9. Its beta is 0.54, indicating the stock historically moves about half as much as the broad market, consistent with a defensive, staples-oriented business. The 8.7% net margin is positive but sits against the backdrop of a fiscal 2026 in which diluted EPS fell 26%, according to the 10-K summary. In other words, the market is applying a roughly 22x multiple to earnings that have recently contracted, implying investors are pricing in either a recovery or the durability of the underlying brand cash flows.

Because ROE is -1,893.5%, traditional ROE-based valuation screens become unusable. An analyst should focus instead on P/E, margin trajectory, free-cash-flow generation, and leverage metrics that are not distorted by negative equity. The low beta supports the idea that Clorox behaves as a defensive holding, but the EPS decline and customer concentration mean profitability can still fall faster than the broader market during a margin squeeze. The data provided does not include a net debt or interest-coverage figure, so any leverage discussion should be anchored to the balance-sheet and cash-flow statements rather than inferred from ROE alone.

Strategic Priorities & Outlook

The company’s most recent 10-K frames near-term priorities around the IGNITE strategy, which has four stated choices: fuel long-term profitable growth, innovate consumer experiences, reimagine how the company and its people work, and continuously evolve the product portfolio. Operationally, management is focused on completing and optimizing a new enterprise resource planning (ERP) system and a broader digital transformation aimed at long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

Other priorities explicitly cited are investing in strong brands and strategic digital capabilities, streamlining the operating model, and advancing the health-and-hygiene expansion with the GOJO integration and growth in professional and institutional markets. The filing also acknowledges that fiscal 2026 saw declines in organic sales and earnings, with diluted EPS down 26%, partly because macroeconomic headwinds coincided with ERP transition timing that had pulled some sales into fiscal 2025. A related portfolio event was the expiration of the Glad bags and wraps venture with Procter & Gamble on January 31, 2026, after which Clorox purchased P&G’s 20% interest, while Glad retained core intellectual property licenses on a royalty-free basis. That transaction changes the economic structure of Glad but keeps the brand’s key licenses intact.

Macro & Geopolitical Exposure

Because Clorox sits in Household & Personal Products, its exposures are those generally tied to packaged-consumer-goods manufacturers rather than a discrete technology or cyclical industrial cycle. Input-cost risk is central: resins, paper and pulp, chemicals, fragrances, packaging materials, and freight/energy costs all flow directly into gross-margin outcomes. When those inputs rise, the company must either raise prices, shrink packaging, or absorb the hit, and the ability to pass costs through depends on brand strength and retail negotiating dynamics.

Regulatory exposure is also inherent to the industry. Disinfectant and cleaning-product claims fall under EPA registration and oversight; personal-care and health-oriented items face FDA and FTC scrutiny around labeling, efficacy claims, and substantiation. Selling into about 95 markets creates currency-translation risk on international revenue and earnings, while tariffs or trade restrictions on chemicals, packaging, and finished goods can shift cost structures.

On the demand side, consumer staples are defensive in volume but not immune to trade-down or private-label substitution when inflation squeezes household budgets. The headline from the August 4, 2026 earnings call flagging inflation fits this framework exactly: even a low-beta staples name can see margin pressure when input and labor costs move together.

Recent Developments

The most recent news cluster centers on Clorox’s August 3, 2026 fourth-quarter report and the August 4, 2026 earnings call. Zacks reported on August 4 that Clorox’s Q4 earnings and sales topped estimates, with GOJO supporting sales. Separately, the same outlet noted that the Q4 earnings call flagged inflation as share recovery builds. That pairing captures the current narrative: revenue is being helped by new health-and-hygiene assets, but management is still talking about cost pressures.

Benzinga reported on August 4 that several analysts raised their forecasts on Clorox following the better-than-expected Q4 results. The actual Q4 numbers showed EPS of $1.66 versus an estimate of $1.64, a 1.2% surprise that produced a 6.52% one-day advance and a 9.61% five-day gain. On August 6, Zacks framed Clorox against Newell Brands in a “NWL vs. CLX: Which Stock Is the Better Value Option?” piece, suggesting the stock is now part of the value-versus-quality debate within the household-products peer group.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Clorox has beaten expectations six times, for a 75% beat rate, with an average earnings surprise of 9.4%. Across those same quarters, the average five-day price move after the report has been 1.67%, classified as an upward post-earnings drift. Those statistics point to a company that usually delivers at or above expectations and tends to see follow-through buying in the days after the release.

Recent individual quarters show more noise than the headline average. The August 3, 2026 report delivered a 1.2% beat ($1.66 vs. $1.64) and a strong 9.61% five-day rally. The May 1, 2026 report also beat ($1.64 vs. $1.55, a 5.8% surprise) but the stock fell 9.67% the next day and 4.49% over the following five days. The February 3, 2026 quarter was a miss ($1.39 vs. $1.43, -2.8%) yet the stock rose 2.43% the next day and 5.63% over five days. The November 3, 2025 quarter beat ($0.85 vs. $0.818, 3.9%) but drifted down 4.08% in the subsequent five sessions. That dispersion is a useful reminder that the average post-earnings drift is positive, but the path is not uniform.

Clorox is scheduled to report next on November 3, 2026, after the market close, with a consensus EPS estimate of $1.07. At the current snapshot, the stock is at $105.395, with an RSI of 59.3 and a 50-day exponential moving average of $99.75. The price sits above that moving average, suggesting near-term technical strength, but the next report’s $1.07 estimate will test whether the sales momentum from GOJO and the recovery narrative can sustain profitability.

For a deeper dive into how institutional analysts, hedge-fund positioning, and options-flow activity are reading Clorox ahead of the November 3, 2026 report, review the full institutional verdict on the platform.